Accuray Incorporated

Accuray Incorporated announced it has entered into agreements with Samsung HME America, Inc., doing business as NeuroLogica Corp., to pursue advanced volumetric imaging capabilities for the CyberKnife System. The collaboration pairs Samsung NeuroLogica's experience in mobile computed tomography and volumetric imaging with Accuray's expertise in precision treatment delivery, robotic radiosurgery, and motion management, and is one component of Accuray's broader strategy to accelerate innovation through a deliberate combination of internally developed technologies and strategic partnerships. The announcement coincides with the American Society of Radiation Oncology Annual Meeting in Boston, where the companies are highlighting the collaboration, and The Royal Marsden NHS Foundation Trust is the first centre worldwide to participate. Accuray President and Chief Executive Officer Steve La Neve said the collaboration reflects clarity about where the company should lead and where it should collaborate, while Samsung HME America Head of Business for Mobile CT Boris Geyzer said the discussion begins with better visualization of anatomy in the treatment room. The collaboration will progress through phased development activities as the companies evaluate technical, clinical, and commercial opportunities, and no commercial product offering has been announced, with future developments subject to ongoing evaluation and applicable regulatory requirements.

Accuray Incorporated and RaySearch Laboratories AB have entered into a definitive agreement for an expanded collaboration aimed at accelerating Accuray's adoption of online adaptive radiation therapy. The collaboration combines Accuray's photon-based radiation therapy platforms and imaging capabilities with RaySearch's treatment planning and workflow software, with the initial focus on Accuray's Radixact platform and future extension to the CyberKnife platform. Under the agreement, Accuray has agreed to purchase specified RayStation licenses with a total order value of USD $8 million to support commercialization of online adaptive radiation therapy solutions, which the two parties will jointly market and support. The collaboration will also leverage RayCare technology to simplify connectivity between clinical systems, and RaySearch will further enhance its software to support the Radixact platform. RaySearch founder and CEO Johan Löf said Accuray's global presence, large installed base, differentiated technology and worldwide service capabilities made them an ideal partner, while Accuray CEO Steve LaNeve said the partnership supports the company's growth strategy and its online adaptive radiation therapy strategy.

The global radiotherapy market is projected to grow from USD 7.98 billion in 2026 to USD 10.68 billion by 2031, at a CAGR of 6.0%, according to a new report by MarketsandMarkets. Growth is driven by rising cancer incidence, increased healthcare investments, and demand for precision oncology, with rapid adoption of technologies such as proton beam therapy, adaptive radiotherapy, and AI-based treatment planning. The systems segment is expected to hold the largest share, while external beam radiotherapy dominates across technology, application, and procedure segments, and hospitals remain the leading end user. Asia Pacific is forecast to register the highest CAGR, supported by expanding oncology infrastructure and government spending in countries including China, India, and Japan. Key players include Siemens Healthineers AG, Elekta, Accuray Incorporated, IBA Worldwide, and ViewRay Technologies.